Vonoprazan
Voquezna (vonoprazan) is a small molecule pharmaceutical. Vonoprazan was first approved as Voquezna triple pak on 2022-05-03. It is used to treat helicobacter pylori in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Voquezna
CombinationsVoquezna dual, Voquezna triple
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA DUAL PAK | Phathom Pharmaceuticals | N-215153 RX | 2022-05-03 | 1 products, RLD, RS |
Amoxicillin
+
Clarithromycin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA TRIPLE PAK | Phathom Pharmaceuticals | N-215152 RX | 2022-05-03 | 1 products, RLD, RS |
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA | Phathom Pharmaceuticals | N-215151 RX | 2023-11-01 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| voquezna | New Drug Application | 2024-07-22 |
| voquezna dual pak voquezna triple pak | New Drug Application | 2024-08-05 |
Indications
FDA
EMA
Show 12 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM | |||
| 2032-05-03 | GAIN | ||
| 2027-05-03 | NCE | ||
AMOXICILLIN / VONOPRAZAN FUMARATE, VOQUEZNA DUAL PAK, PHATHOM | |||
| 2032-05-03 | GAIN | ||
| 2027-05-03 | NCE | ||
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC08: Vonoprazan
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD14: Vonoprazan, amoxicillin and clarithromycin
— A02BD15: Vonoprazan, amoxicillin and metronidazole
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 3 | 2 | 5 | 24 | 15 | 48 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 2 | 3 | 3 | 8 | 11 | 26 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 5 | 2 | 3 | 3 | 4 | 17 |
| Ulcer | D014456 | MPATH_579 | — | 1 | — | 11 | 1 | 3 | 16 |
| Esophagitis | D004941 | HP_0100633 | K20 | 2 | — | 7 | 2 | 4 | 15 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | 2 | — | 3 | 7 | 2 | 14 |
| Stomach ulcer | D013276 | — | K25 | 1 | — | 8 | 1 | 2 | 12 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 5 | 4 | 10 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 2 | — | 2 | 2 | 3 | 9 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | 1 | 1 | — | 3 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | — | 8 | — | 4 | 12 |
| Healthy volunteers/patients | — | — | — | 8 | — | 1 | — | — | 9 |
| Heartburn | D006356 | — | R12 | 1 | 1 | 1 | — | 1 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | 1 | — | — | 1 |
| Treatment outcome | D016896 | — | — | — | — | 1 | — | — | 1 |
| Adolescent development | D041923 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | — | — | 2 | 2 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | — | — | — | 1 | 1 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | — | — | 1 | 1 |
| Thrombocytopenic purpura | D011696 | — | — | — | — | — | — | 1 | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | — | — | — | 1 | 1 |
| Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vonoprazan |
| INN | vonoprazan |
| Description | Vonoprazan is a member of pyrroles. |
| Classification | Small molecule |
| Drug class | proton pump inhibitors, not dependent on acid activation |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 881681-00-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2079130 |
| ChEBI ID | — |
| PubChem CID | 15981397 |
| DrugBank | DB11739 |
| UNII ID | 1R5L3J156G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Voquezna – Phathom Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,211 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
609 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use